By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Oncology. According to news originating from Jammu, India, by NewsRx correspondents, research stated, "Magnetic drug targeting is a drug delivery system that can be used in loco-regional cancer treatment. Coated magnetic particles, called carriers, are very useful for delivering chemotherapeutic drugs."
Our news journalists obtained a quote from the research from the University of Jammu, "Magnetic carriers were synthesized by co-precipitation of iron oxide followed by coating with polyvinyl pyrrolidone (PVP). Characterization was performed using X-ray diffraction, TEM, TGA, FTIR and UV-Vis Spectroscopy. Magnetite (Fe3O4) remained as the core of the carrier. The amount of PVP bound to the iron oxide nanoparticles was estimated by thermogravimetric analysis (TGA) and the attachment of PVP to the iron oxide nanoparticles confirmed by FTIR analysis. The loading efficiency of Epirubicin hydrochloride onto the PVP coated and uncoated iron oxide nanoparticles was measured at intervals such as 1 hr and 24 hrs by UV-Vis Spectroscopy. The binding of Epirubicin hydrochloride to the PVP coated and uncoated iron oxide nanoparticles were confirmed by FTIR analysis. The present findings showed that Epirubicin hydrochloride loaded PVP coated iron oxide nanoparticles are promising for magnetically targeted drug delivery."
According to the news editors, the research concluded: "The drug displayed increased cell cytotoxicity at lower concentrations when conjugated with the nanoparticles than being administered conventionally as individual drugs."
For more information on this research see: Drug Embedded PVP Coated Magnetic Nanoparticles for Targeted Killing of Breast Cancer Cells. Technology in Cancer Research & Treatment, 2013;12(5):463-472. Technology in Cancer Research & Treatment can be contacted at: Adenine Press, 2066 Central Ave, Schenectady, NY 12304, USA (see also Oncology).
The news correspondents report that additional information may be obtained from P.A. Rose, Univ Jammu, Sch Biotechnol, Jammu 180004, India. Additional authors for this research include P.K. Praseetha, M. Bhagat, P. Alexander, S. Abdeen and M. Chavali.
Keywords for this news article include: Asia, Jammu, India, Oncology, Epirubicin, Doxorubicin, Naphthacenes, Breast Cancer, Anthracyclines, Women's Health
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC